Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CTNM

Contineum Therapeutics Inc

Feb 13 • 04:00PM ET

14.44

-0.44 -2.96 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB GILD AMGN MRNA BMY LLY PFE JNJ

| Held by: VTI IBB VXF SCHA IWC AVSC SCHB AVTM IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-2.26	Insider Own	27.80%	Shs Outstand	36.53M	Perf Week	-3.73%
Market Cap	527.49M	Forward P/E	-	EPS next Y	-2.20	Insider Trans	-0.20%	Shs Float	26.38M	Perf Month	22.79%
Enterprise Value	350.57M	PEG	-	EPS next Q	-0.39	Inst Own	41.66%	Short Float	9.84%	Perf Quarter	25.89%
Income	-59.39M	P/S	-	EPS this Y	5.82%	Inst Trans	5.98%	Short Ratio	10.25	Perf Half Y	98.90%
Sales	0.00M	P/B	2.33	EPS next Y	-7.10%	ROA	-29.19%	Short Interest	2.60M	Perf YTD	26.33%
Book/sh	6.18	P/C	2.89	EPS next 5Y	1.35%	ROE	-30.40%	52W High	16.01 -9.81%	Perf Year	87.78%
Cash/sh	4.99	P/FCF	-	EPS past 3/5Y	-30.13% -	ROIC	-32.19%	52W Low	3.35 331.04%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.28% 7.99%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-100.71%	Oper. Margin	-	ATR (14)	1.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	29.07	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	57.19	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	29.07	EPS Q/Q	-14.06%	SMA20	2.70%	Beta	1.09	Target Price	20.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	16.23%	Rel Volume	0.51	Prev Close	14.88
Employees	41	LT Debt/Eq	0.02	Earnings	Oct 30 AMC	SMA200	60.29%	Avg Volume	253.39K	Price	14.44
IPO	Apr 05, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.99% -100.00%	Trades		Volume	130,484	Change	-2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$14
Nov-13-25	Initiated	Leerink Partners	Outperform	$22
Sep-25-25	Initiated	Leerink Partners	Outperform	$20
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform	$32
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Feb-04-26 09:40AM	Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-28-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 12:00PM	Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? (Zacks)
Dec-11-25 10:24PM	Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering (Business Wire) -11.02%
04:05PM	Loading…
04:05PM	Contineum Therapeutics Announces Proposed $75.0 Million Public Offering (Business Wire)
Nov-24-25 04:05PM	Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference (Business Wire) -5.34%
Nov-21-25 01:44AM	A brain biotechs top drug fails against MS (BioPharma Dive) -10.43%
Nov-20-25 04:05PM	Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Oct-30-25 04:05PM	Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Sep-18-25 08:05AM	Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Aug-28-25 04:05PM	Contineum Therapeutics to Present at September Investor Conferences (Business Wire)
Aug-08-25 09:55AM	Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet (Zacks)
Aug-05-25 04:05PM	Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones (Business Wire) +5.50%
Jun-25-25 08:15AM	Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
04:05PM	Loading…
May-15-25 04:05PM	Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire) -10.91%
May-14-25 04:05PM	Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Apr-28-25 04:05PM	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development (Business Wire)
Mar-17-25 04:05PM	Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors (Business Wire) +5.85% +6.09%
Mar-12-25 04:05PM	Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum (Business Wire) -5.56%
Mar-06-25 04:05PM	Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) +5.57% +5.12%
Mar-04-25 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 (Business Wire) -5.16%
Mar-03-25 04:05PM	Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference (Business Wire) -6.39%
Jan-08-25 04:05PM	Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Jan-06-25 08:00AM	RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors (GlobeNewswire)
Dec-16-24 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Nov-25-24 08:05AM	Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference (Business Wire) +9.01%
Nov-18-24 08:05AM	Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain (Business Wire) -8.02%
Nov-13-24 04:05PM	Contineum Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-06-24 04:05PM	Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +7.60%
04:05PM	Loading…
Aug-28-24 04:05PM	Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences (Business Wire) -7.00%
Aug-13-24 04:05PM	Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -6.06% +6.21%
Jul-31-24 04:05PM	Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis (Business Wire) -5.33%
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stengone Carmine N.	CEO and President	Feb 11 '26	Option Exercise	1.26	400	504	15,354	Feb 13 04:27 PM
Stengone Carmine N.	CEO and President	Feb 11 '26	Sale	16.00	400	6,400	14,954	Feb 13 04:27 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 11 '26	Option Exercise	1.01	400	404	156,452	Feb 13 04:26 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 11 '26	Sale	16.00	400	6,400	156,052	Feb 13 04:26 PM
DANIEL LORRAIN	Officer	Feb 11 '26	Proposed Sale	15.75	16,050	252,788		Feb 11 04:29 PM
CARMINE STENGONE	Director	Feb 11 '26	Proposed Sale	15.75	7,500	118,125		Feb 11 04:29 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 03 '26	Sale	14.94	4,170	62,305	156,052	Feb 05 04:24 PM
DANIEL LORRAIN	Officer	Feb 03 '26	Proposed Sale	14.38	4,170	59,965		Feb 03 04:32 PM
Watkins Tim	CMO & Head of Development	Jan 28 '26	Option Exercise	4.50	3,611	16,250	3,611	Jan 30 04:52 PM
Watkins Tim	CMO & Head of Development	Jan 28 '26	Sale	14.18	3,611	51,188	0	Jan 30 04:52 PM
Lorrain Daniel S.	Chief Scientific Officer	Jan 05 '26	Sale	10.44	4,170	43,543	160,222	Jan 06 04:16 PM
DANIEL LORRAIN	Officer	Jan 05 '26	Proposed Sale	11.39	4,170	47,496		Jan 05 04:42 PM
Watkins Tim	CMO & Head of Development	Dec 29 '25	Option Exercise	4.50	3,611	16,250	3,611	Dec 30 04:12 PM
Watkins Tim	CMO & Head of Development	Dec 29 '25	Sale	12.06	3,611	43,558	0	Dec 30 04:12 PM
Lorrain Daniel S.	Chief Scientific Officer	Dec 23 '25	Sale	12.23	4,170	51,009	164,392	Dec 30 04:10 PM
TIMOTHY WATKINS	Officer	Dec 29 '25	Proposed Sale	12.41	10,833	134,438		Dec 29 04:25 PM
DANIEL LORRAIN	Officer	Dec 23 '25	Proposed Sale	12.26	4,170	51,124		Dec 23 04:20 PM

Open in Screener

KPRX

Kiora Pharmaceuticals Inc

Feb 13 • 04:00PM ET

2.08

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

KPRX Kiora Pharmaceuticals Inc daily Stock Chart

Peers: ARWR RGEN EYPT OCUL CLSD ALDX PRQR IRD VSTM PULM

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	8.72%	Shs Outstand	3.43M	Perf Week	-3.26%
Market Cap	7.65M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	0.00%	Shs Float	3.36M	Perf Month	-6.31%
Enterprise Value	-11.33M	PEG	-	EPS next Q	-0.67	Inst Own	37.30%	Short Float	0.40%	Perf Quarter	-9.76%
Income	-8.54M	P/S	-	EPS this Y	-296.55%	Inst Trans	-8.12%	Short Ratio	0.24	Perf Half Y	-17.79%
Sales	0.00M	P/B	0.32	EPS next Y	-30.41%	ROA	-24.99%	Short Interest	0.01M	Perf YTD	5.58%
Book/sh	6.53	P/C	0.39	EPS next 5Y	-	ROE	-32.58%	52W High	4.18 -50.24%	Perf Year	-42.22%
Cash/sh	5.27	P/FCF	-	EPS past 3/5Y	- -	ROIC	-37.70%	52W Low	1.76 17.88%	Perf 3Y	-96.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 42.93%	Gross Margin	-	Volatility	4.81% 5.53%	Perf 5Y	-99.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-463.97%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	8.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.90	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.79	EPS Q/Q	100.77%	SMA20	-4.89%	Beta	-0.79	Target Price	12.00
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-2.45%	Rel Volume	0.15	Prev Close	2.08
Employees	12	LT Debt/Eq	0.01	Earnings	Nov 07 BMO	SMA200	-19.79%	Avg Volume	55.12K	Price	2.08
IPO	Feb 13, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	101.36% -100.00%	Trades		Volume	8,278	Change	0.00%

Jan-27-26 07:00AM	Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Dec-01-25 06:45AM	Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds (Newsfile)
Nov-07-25 06:00AM	Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
Oct-30-25 09:00AM	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders (PR Newswire)
Oct-15-25 07:00AM	Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 (Newsfile)
07:00AM	Loading…
Sep-04-25 07:00AM	Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-08-25 07:00AM	Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
Aug-07-25 07:00AM	Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Newsfile)
Aug-01-25 11:51AM	Vicarious Surgical names Stephen From as next CEO (MedTech Dive)
Jul-31-25 04:30PM	Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer (Business Wire)
Jul-22-25 08:55AM	Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease (Newsfile)
Jul-16-25 12:00PM	Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +5.00%
Jun-03-25 07:00AM	Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia (Newsfile) +36.84%
May-09-25 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Newsfile)
May-05-25 07:00AM	Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Newsfile)
07:00AM	Loading…
Apr-04-25 07:00AM	Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference (Newsfile) -7.31%
Mar-25-25 07:00AM	Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 (Newsfile) -5.00%
Mar-12-25 07:00AM	Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting (Newsfile)
Feb-13-25 07:00AM	Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 (Newsfile)
Feb-11-25 06:45AM	Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema (Newsfile) -9.44%
Nov-08-24 07:00AM	Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies (Newsfile)
Oct-30-24 07:28AM	Kiora Pharmaceuticals Gains Approval for Phase 2 Trial (TipRanks)
Oct-29-24 06:45AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa (Newsfile)
Sep-25-24 09:55AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Aug-09-24 02:53PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies (Newsfile)
Aug-06-24 07:03AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Jul-30-24 06:45AM	Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies (Newsfile)
Jul-10-24 07:00AM	Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation (Newsfile)
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
06:45AM	Loading…
Jun-25-24 06:45AM	Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)
Nov-09-22 06:45AM	Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End (Newsfile) -5.76%
Oct-31-22 08:01AM	KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 (News Direct)
Oct-17-22 08:00AM	Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease (Newsfile)
Oct-13-22 06:45AM	Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (Newsfile)
Sep-28-22 11:44AM	Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D. (Newsfile) +6.06%
Sep-26-22 06:45AM	Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split (Newsfile) -10.05%
Sep-13-22 06:45AM	Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance (Newsfile) +21.00%
Aug-15-22 06:30AM	KPRX: What a difference a year makes! (Zacks Small Cap Research)
Aug-12-22 06:45AM	Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results (Newsfile) -10.71%
Jul-28-22 06:45AM	Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics (Newsfile)
Jul-26-22 04:38PM	Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile)
Jul-22-22 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering (Newsfile) -39.76%

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

CTNM

Contineum Therapeutics Inc

KPRX

Kiora Pharmaceuticals Inc

Upgrade your FINVIZ experience